Navigation Links
Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Date:4/24/2012

se. To address the challenge of the unique genetic profile of each patient´s disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient´s disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is fully personalized for each patient's disease.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. 

Contact:

David Schull or Andreas Marathovouniotis
Russo Partners LLC
(212) 845-4271 or (212) 845-4235
david.schull@russopartnersllc.com or andreas.marathis@russopartnersllc.com

Jeff Abbey
Argos Therapeutics
(919) 287-6308
jabbey@argostherapeutics.com

 


'/>"/>
SOURCE Argos Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
2. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
3. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
4. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
5. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
6. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
7. Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
8. Argos Therapeutics Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... Aug. 28, 2014  A candidate Ebola vaccine could be given ... and Mali as early as September, ... aimed at preventing the disease that has killed more than 1,400 ... . Human trials of this candidate vaccine, being co-developed ... to be accelerated with funding from an international consortium in response ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Ebola vaccine trials fast-tracked by international consortium 2Ebola vaccine trials fast-tracked by international consortium 3Ebola vaccine trials fast-tracked by international consortium 4Ebola vaccine trials fast-tracked by international consortium 5Ebola vaccine trials fast-tracked by international consortium 6Ebola vaccine trials fast-tracked by international consortium 7
... of its commitment to supporting efforts to improve the ... has awarded $1,000 grants to ten health care organizations ... issues. (Logo: http://photos.prnewswire.com/prnh/20100412/DA84842LOGO ) ... the 2010 Beryl Institute Patient Experience grants are: ...
... PITTSBURGH, Oct. 19 Mylan Inc. (Nasdaq: MYL ... preferred stock issuance, the company has declared its quarterly dividend ... of 6.5% and a liquidation preference of $1,000.00 per share) ... of record as of Nov. 1, 2010.  Nov. 15, is ...
Cached Medicine Technology:Patient Experience Research Grants Awarded 2Patient Experience Research Grants Awarded 3
(Date:8/29/2014)... 2014 Most dentists work during normal business ... break in their day to be able to go see ... to find a few hours during their increasingly busy days. ... so important. It is now possible for people to get ... What is happening? , North York Dental has realized that ...
(Date:8/29/2014)... Washington MD (PRWEB) August 29, 2014 ... Expo at the Hyatt Regency Orlando last week August ... Greenstein returned as a presenter. , ... Reform in the 21st Century was a standing room ... Ah-hah Moments – Doctors of Chiropractic Leading the Way ...
(Date:8/29/2014)... 2014 Recent reports, backed by the ... today are working longer hours and taking fewer vacations ... Water believes that drinking lots of purified water can ... on their most popular and effective water purification systems ... until 9/2/2014, customers can save up to $125 off ...
(Date:8/29/2014)... 29, 2014 The Winscribe Board of ... Chief Executive Officer effective from 1st September 2014. Allen ... Winscribe. , “During this time of growth, there is ... said Matthew Weavers, Winscribe’s Founder and Chairman of the ... of commercial, IT and management experience gained in New ...
(Date:8/28/2014)... Fifty percent of adults who seek medical ... percent of Americans claim to have fatigue that is ... Fatigue is the most common yet overlooked cause of ... symptoms. Tasks that were once a breeze are now ... cause irritation, experiencing weight gain around the middle area ...
Breaking Medicine News(10 mins):Health News:North York Dental Provides Dental Services to Busy Professionals 2Health News:Sport and Spine Rehab’s CEO Presents at the Florida Chiropractic Association National Convention and Expo 2014 2Health News:Relax this Labor Day Weekend with Great Savings on Easy-Install, Do-It-Yourself Drinking and Whole House Water Filters 2Health News:Winscribe Names Greg Allen as CEO 2Health News:Peoria AlignLife Clinics Focus on Community Education 2
... E. Lachman has been awarded a $1.45 million five-year ... more about factors that can minimize memory declines in ... beliefs and behaviors that are tied to better memory ... and older adults believe that memory declines are inevitable ...
... Jobson Medical Information LLC,("JMI"), a leading ... it has acquired Gerber Communications ("Gerber") and,Practice ... leading,providers of custom publishing services and training ... acquisition expands JMI,s ability to,reach eye care ...
... Medical Center today,announced the use of an investigational, ... treatment of heart rhythm,disorders that can result in ... first performed in Texas as part of the ... taking place at up,to 25 hospitals throughout the ...
... other systemic uses of drugs to ... growth factor (VEGF), BOSTON, Feb. 13 New research ... the anti-cancer drug Avastin,which targets a growth factor responsible for ... certain patients.,Institute scientists mimicked the drug,s activity in mice and ...
... speech,pathologist and autism consultant Valerie Herskowitz will present ... the "Autism Through,the Lifespan" conference to be held ... now for an entire generation of children challenged ... and becoming young,adults with autism. Technology is the ...
... MALVERN, Pa., Feb. 13 A new study ... medical expenses reported,by auto injury claimants continue to ... economic losses (which include expenses for,medical care, lost ... claimants grew 9 percent annualized, from $5,520 in ...
Cached Medicine News:Health News:Brandeis researcher awarded grant to investigate memory and aging 2Health News:Jobson Medical Information LLC Acquires Gerber Communications and Practice Advancement Associates 2Health News:St. David's Medical Center First in Texas to Implement Visually Guided Catheter Ablation for Atrial Fibrillation 2Health News:VEGF Neutralization Can Damage Brain Vessels, Say Schepens Eye Research Institute Scientists 2Health News:A Sneak Peek Into the Special Needs Home of Tomorrow - Renowned Autism Consultant Valerie Herskowitz to Present Latest Findings at 'Autism Through the Lifespan' Conference February 14-17 in Orlando 2Health News:IRC Reports Claimed Medical Expenses for Auto Injury Claimants Far Outpace Inflation 2
15mm Open Blades, 28mm Maximum Spread; Available in small(S) and large (L), in stainless steel....
9mm Gently Curved Jaws, without lock; in Titanium....
8mm angled shaft with tip at 90 degree angle wtih rounded tear drop point; Tip available in left, right and center; (Right-SQT-225 and Left -SQT-227) In Titanium....
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Medicine Products: